Currently, while the utilization of L1CAM as a target protein for isolation and enrichment of brain‐derived EVs has garnered significant attention, particularly in the context of its potential diagnostic and therapeutic applications across various neurological disorders, there remains a paucity of studies investigating the quantitative association between the expression level of L1CAM on EVs and PD, particularly regarding large‐scale clinical validation. This evidence concerns the gene L1CAM and Parkinson disease.